Drug Safety

, Volume 27, Issue 3, pp 203–213 | Cite as

The Risk of Severe Depression, Psychosis or Panic Attacks with Prophylactic Antimalarials

  • Christoph R. Meier
  • Karen Wilcock
  • Susan S. Jick
Original Research Article


Introduction/Objective: Experimental and observational studies have linked mefloquine use to an increased risk of developing neuropsychiatric adverse effects such as depression or psychoses. Most of these reports relied on interview-based information from travellers. We conducted a population-based observational study using a database of medical records to quantify and compare the risk of psychiatric disorders during or after use of mefloquine with the risk during use of proguanil and/or chloroquine, or doxycycline.

Study Design/Methods: The study population was drawn from the large UK-based General Practice Research Database (GPRD). Subjects were aged from 17–79 years and were exposed to mefloquine, proguanil, chloroquine or doxycycline (or a combination of these drugs) at some time between 1990 and 1999. We performed a person-time and a nested case-control analysis to assess the risk of developing a first-time diagnosis of depression, psychosis or panic attack during or after use of these antimalarial drugs.

Results: Within the study population of 35 370 subjects (45.2% males), we identified 580 subjects with a first-time diagnosis of depression (n = 505), psychosis (n = 16) or panic attack (n = 57) and two subjects committed suicide. The incidence rates of first-time diagnoses of depression during current use of mefloquine, proguanil and/or chloroquine, or doxycycline, adjusted for age, gender and calendar year, were 6.9 (95% CI 4.5–10.6), 7.6 (95% CI 5.5–10.5) and 9.5 (95% CI 3.7–24.1)/1000 person-years, respectively. The incidence rates of psychosis or panic attacks during current mefloquine exposure were 1.0/1000 person-years (95% CI 0.3–2.9) and 3.0/1000 person-years (95% CI 1.6–5.7), respectively, approximately 2-fold higher (statistically nonsignificant) than during current use of proguanil and/or chloroquine, or doxycycline. The nested case-control analysis encompassed 505 cases with depression and 3026 controls, 16 cases with psychosis and 96 controls, and 57 cases with a panic attack and 342 controls. Current use of mefloquine was not associated with an elevated risk of developing depression. In a comparison between patients currently using mefloquine with all past users of antimalarials combined, the risk estimate was elevated for current users of mefloquine for both psychosis (odds ratio [OR] 8.0, 95% CI 1.0–62.7; p < 0.05) and panic attacks (OR 2.7, 95% CI 1.1–6.5; p < 0.05).

Conclusion: The absolute risk of developing psychosis or panic attack appears low with all the antimalarials tested. No evidence was found in this large observational study that mefloquine use increased the risk of first-time diagnosis of depression when compared with the use of other antimalarials investigated in this study.


Doxycycline Chloroquine Index Date Antimalarial Drug Mefloquine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was funded by an unconditional grant by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Dr Karen Wilcock, who is employed by Roche, had substantial scientific input and was involved in the study design and interpretation of the data.


  1. 1.
    Barrett PJ, Emmins PD, Clarke PD, et al. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ 1996; 313: 525–8PubMedCrossRefGoogle Scholar
  2. 2.
    Durrheim DN, Gammon S, Waner S, et al. Antimalarial prophylaxis: use and adverse events in visitors to the Kruger National Park. S Afr Med J 1999; 89: 170–5PubMedGoogle Scholar
  3. 3.
    Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993; 341(8856): 1299–303PubMedCrossRefGoogle Scholar
  4. 4.
    Croft AMJ, World MJ. Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet 1996; 347(8997): 326–8PubMedCrossRefGoogle Scholar
  5. 5.
    Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993; 44(3): 257–65PubMedGoogle Scholar
  6. 6.
    Corbett EL, Doherty JF, Behrens RH. Adverse events associated with mefloquine [letter]. BMJ 1996; 313: 1552PubMedCrossRefGoogle Scholar
  7. 7.
    Hoebe C, de Munter J, Thijs C. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol 1997; 52: 269–75PubMedCrossRefGoogle Scholar
  8. 8.
    Petersen E, Ronne T, Ronn A, et al. Reported side effects to chloroquine, chloroquine plus proguanil and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Travel Med 2000; 7: 79–84PubMedCrossRefGoogle Scholar
  9. 9.
    Van Riemsdijk MM, van der Klauw MM, van Heest JAC, et al. Neuro-psychiatric effects of antimalarials. Eur J Clin Pharmacol 1997; 52: 1–6PubMedCrossRefGoogle Scholar
  10. 10.
    Corominas N, Gascon J, Meijas T, et al. Adverse drug reactions associated to the antimalarial chemoprophylaxis. Med Clin (Barc) 1997; 108: 772–5Google Scholar
  11. 11.
    Carme B, Peguet C, Nevez G. Compliance and tolerance of mefloquine and chloroquine + proguanil chemoprophylaxis in French short-term travelers to Africa. Bull Soc Pathol Exot 1997; 90(4): 273–6PubMedGoogle Scholar
  12. 12.
    Huzly D, Schonfeld C, Beuerle W, et al. Malaria Chemoprophylaxis in German Tourists: a prospective study on compliance and adverse reactions. J Travel Med 1996; 3: 148–55PubMedCrossRefGoogle Scholar
  13. 13.
    Peregallo MS, Sabatinelli G, Sarnicola G. Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military). Trans R Soc Trop Med Hyg 1999; 93: 73–7CrossRefGoogle Scholar
  14. 14.
    Wolters BA, Bosje T, Luinstra-Passchier MJ. No more problems with mefloquine compared to other antimalarial prophylactics. Ned Tijdschr Geneesk 1997; 141(7): 331–4Google Scholar
  15. 15.
    Angles A, Bagheri H, Montastruc JL, et al. Adverse drug reactions (ADRs) to antimalarial drugs: analysis of spontaneous report from the French pharmacovigilance database (1996-2000). Presse Med 2003; 32: 106–13PubMedGoogle Scholar
  16. 16.
    Lobel HO, Baker MA, Gras FA, et al. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med 2001; 8: 167–72PubMedCrossRefGoogle Scholar
  17. 17.
    Dietz A, Frolich L. Mefloquine-induced paranoid psychosis and subsequent major depression in a 25-year-old student. Pharmacopsychiatry 2002; 35: 200–2PubMedCrossRefGoogle Scholar
  18. 18.
    Fuller SJ, Naraqi S, Gilessi G. Paranoid psychosis related to mefloquine antimalarial prophylaxis. PNG Med J 2002; 45: 219–21Google Scholar
  19. 19.
    Potasman I, Beny A, Seligmann H. Neuropsychiatric problems in 2500 long-term young travelers to the tropics. J Travel Med 2000; 7: 5–9PubMedCrossRefGoogle Scholar
  20. 20.
    van Riemsdijk MM, Ditters JM, Sturkenboom MCJM, et al. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 2002; 58: 441–5PubMedCrossRefGoogle Scholar
  21. 21.
    Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33: 1015–21PubMedCrossRefGoogle Scholar
  22. 22.
    Croft AMJ, Garner P. Mefloquine for preventing malaria in nonimmune adult travelers (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2003Google Scholar
  23. 23.
    Murphy JM, Laird NM, Monson RR, et al. Incidence of depression in the Stirling County Study: historical and comparative perspectives. Psychol Med 2000; 30: 505–14PubMedCrossRefGoogle Scholar
  24. 24.
    Hagnell O, Lanke J, Rorsman B, et al. Are we entering an age of melancholy? Depressive illnesses in a prospective epidemiological study over 25 years: the Lundby Study, Sweden. Psychol Med 1982; 12: 279–89PubMedCrossRefGoogle Scholar
  25. 25.
    Jenkins R, Lewis G, Bebbington P, et al. The National Psychiatric Morbidity Surveys of Great Britain: initial findings from the Household Survey. Psychol Med 1997; 27(4): 775–89PubMedCrossRefGoogle Scholar
  26. 26.
    Lepine J-P, Gastpar M, Mendlewicz J, et al. Depression in the Community: the First Pan-European Study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12: 19–29PubMedCrossRefGoogle Scholar
  27. 27.
    Widerlov B, Lindstrom E, von Knorring L. One-year prevalence of long-term functional psychosis in three different areas of Uppsala. Acta Psychiatr Scand 1997; 96(6): 452–8PubMedCrossRefGoogle Scholar
  28. 28.
    Ruggeri M, Morven L, Thornicroft G, et al. Definition and prevalence of severe and persistent mental illness. Br J Psychiatry 2000; 177: 149–55PubMedCrossRefGoogle Scholar
  29. 29.
    Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 1097–9PubMedCrossRefGoogle Scholar
  30. 30.
    Jick H. A database worth saving. Lancet 1997; 350: 1045–6PubMedCrossRefGoogle Scholar
  31. 31.
    Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766–8PubMedCrossRefGoogle Scholar
  32. 32.
    Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347–9CrossRefGoogle Scholar
  33. 33.
    Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686–9PubMedCrossRefGoogle Scholar
  34. 34.
    Dierker LC, Avenevoli S, Stolar M, et al. Smoking and depression: an examination of mechanisms of comorbidity. Am J Psychiatry 2002; 159: 947–53PubMedCrossRefGoogle Scholar
  35. 35.
    Goodwin R, Hamilton SP. Cigarette smoking and panic: the role of neuroticism. Am J Psychiatry 2002; 159: 1208–13PubMedCrossRefGoogle Scholar
  36. 36.
    Wittes RC, Saginur R. Adverse reaction to mefloquine associated with ethanol ingestion. CMAJ 1995; 152: 515–7PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Christoph R. Meier
    • 1
    • 2
  • Karen Wilcock
    • 3
  • Susan S. Jick
    • 2
  1. 1.Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, Department of Internal MedicineUniversity Hospital BaselBaselSwitzerland
  2. 2.Boston Collaborative Drug Surveillance ProgramBoston University Medical CenterLexingtonUSA
  3. 3.F. Hoffmann-La Roche Ltd, Pharmaceuticals DivisionBaselSwitzerland

Personalised recommendations